POR
Basic information
Region (hg38): 7:75899200-75986855
Links
Phenotypes
GenCC
Source:
- Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis (Strong), mode of inheritance: AR
- Antley-Bixler syndrome (Supportive), mode of inheritance: AD
- congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency (Supportive), mode of inheritance: AR
- congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency (Strong), mode of inheritance: AR
- Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis; Disordered steroidogenesis due to cytochrome P450 oxidoreductase deficiency | AR | Endocrine | Hydrocortisone replacement therapy can be effective for cortisol deficiency, including administation of stress-dose steroids; In males, testosterone therapy can help with undervirilization in puberty | Craniofacial; Endocrine; Genitourinary; Musculoskeletal; Neurologic | 2932643; 0633130; 12116245; 11742006; 12917333; 15220035; 14758361; 14513299; 15793702; 16906539; 18559916; 19837910; 19884324; 20124576; 20410220; 20818252; 20844025; 21070833; 22162478 |
ClinVar
This is a list of variants' phenotypes submitted to
- Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency (44 variants)
- Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis (3 variants)
- Congenital adrenal hyperplasia (3 variants)
- not provided (2 variants)
- POR-related disorder (2 variants)
- Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency;Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis;Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the POR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 231 | 238 | ||||
missense | 155 | 166 | ||||
nonsense | 12 | 14 | ||||
start loss | 0 | |||||
frameshift | 29 | 32 | ||||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 15 | 17 | ||||
splice region | 11 | 38 | 49 | |||
non coding | 18 | 159 | 29 | 206 | ||
Total | 46 | 25 | 178 | 394 | 35 |
Highest pathogenic variant AF is 0.000210
Variants in POR
This is a list of pathogenic ClinVar variants found in the POR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-75915104-A-C | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Jan 12, 2018) | ||
7-75915137-A-C | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Benign (Jan 12, 2018) | ||
7-75915138-G-C | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Jan 15, 2018) | ||
7-75915151-G-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Jan 13, 2018) | ||
7-75915179-G-A | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency • POR-related disorder | Uncertain significance (Jan 12, 2018) | ||
7-75915179-G-C | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Jan 13, 2018) | ||
7-75915179-G-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Jan 13, 2018) | ||
7-75915187-C-G | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Jan 13, 2018) | ||
7-75915188-T-C | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Apr 27, 2017) | ||
7-75915189-A-G | POR-related disorder | Likely benign (Feb 25, 2019) | ||
7-75915190-T-C | POR-related disorder | Likely benign (Jan 05, 2021) | ||
7-75954006-G-C | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Aug 30, 2023) | ||
7-75954007-A-G | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis • Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Benign (Feb 01, 2024) | ||
7-75954016-C-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (May 02, 2023) | ||
7-75954034-C-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (Jul 13, 2023) | ||
7-75954035-G-A | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Mar 08, 2022) | ||
7-75954037-G-A | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (Aug 29, 2023) | ||
7-75954040-C-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (Nov 08, 2023) | ||
7-75954041-G-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Pathogenic (Nov 30, 2023) | ||
7-75954045-C-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Uncertain significance (Oct 04, 2022) | ||
7-75954046-G-A | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (Jan 29, 2024) | ||
7-75954052-C-G | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (May 22, 2023) | ||
7-75954052-C-T | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (Jul 19, 2022) | ||
7-75954061-A-G | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Likely benign (Mar 19, 2023) | ||
7-75954061-ATC-A | Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency | Pathogenic (Mar 28, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
POR | protein_coding | protein_coding | ENST00000461988 | 15 | 87656 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.42e-10 | 0.981 | 124568 | 0 | 92 | 124660 | 0.000369 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.0717 | 448 | 444 | 1.01 | 0.0000306 | 4384 |
Missense in Polyphen | 125 | 141.01 | 0.88647 | 1301 | ||
Synonymous | -0.668 | 214 | 202 | 1.06 | 0.0000162 | 1303 |
Loss of Function | 2.31 | 21 | 35.9 | 0.585 | 0.00000187 | 381 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000736 | 0.000695 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000224 | 0.000223 |
Finnish | 0.000125 | 0.0000928 |
European (Non-Finnish) | 0.000499 | 0.000478 |
Middle Eastern | 0.000224 | 0.000223 |
South Asian | 0.000439 | 0.000425 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5. {ECO:0000255|HAMAP- Rule:MF_03212}.;
- Disease
- DISEASE: Antley-Bixler syndrome, with genital anomalies and disordered steroidogenesis (ABS1) [MIM:201750]: A disease characterized by the association of Antley-Bixler syndrome with steroidogenesis defects and abnormal genitalia. Antley-Bixler syndrome is characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. {ECO:0000269|PubMed:14758361, ECO:0000269|PubMed:15264278, ECO:0000269|PubMed:15483095}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Disordered steroidogenesis due to cytochrome P450 oxidoreductase deficiency (DISPORD) [MIM:613571]: A disorder resulting in a rare variant of congenital adrenal hyperplasia, with apparent combined P450C17 and P450C21 deficiency and accumulation of steroid metabolites. Affected girls are born with ambiguous genitalia, but their circulating androgens are low and virilization does not progress. Conversely, affected boys are sometimes born undermasculinized. Boys and girls can present with bone malformations, in some cases resembling the pattern seen in patients with Antley-Bixler syndrome. {ECO:0000269|PubMed:14758361, ECO:0000269|PubMed:15220035}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Doxorubicin Pathway, Pharmacokinetics;Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics;Doxorubicin Metabolism Pathway;Integrated Lung Cancer Pathway;Oxidation by Cytochrome P450;Phase I - Functionalization of compounds;oxidative stress induced gene expression via nrf2;Cytochrome P450 - arranged by substrate type;Biological oxidations;Metabolism;superpathway of tryptophan utilization;bile acid biosynthesis, neutral pathway;vitamin D<sub>3</sub> biosynthesis;melatonin degradation I;superpathway of melatonin degradation
(Consensus)
Recessive Scores
- pRec
- 0.542
Intolerance Scores
- loftool
- 0.329
- rvis_EVS
- -1.52
- rvis_percentile_EVS
- 3.43
Haploinsufficiency Scores
- pHI
- 0.165
- hipred
- N
- hipred_score
- 0.492
- ghis
- 0.489
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.986
Mouse Genome Informatics
- Gene name
- Por
- Phenotype
- cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; renal/urinary system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); craniofacial phenotype; vision/eye phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype;
Gene ontology
- Biological process
- regulation of growth plate cartilage chondrocyte proliferation;xenobiotic metabolic process;response to nutrient;carnitine metabolic process;response to hormone;flavonoid metabolic process;internal peptidyl-lysine acetylation;fatty acid oxidation;electron transport chain;positive regulation of chondrocyte differentiation;positive regulation of monooxygenase activity;response to drug;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;nitrate catabolic process;positive regulation of cholesterol biosynthetic process;positive regulation of smoothened signaling pathway;nitric oxide catabolic process;oxidation-reduction process;negative regulation of lipase activity;demethylation;cellular response to follicle-stimulating hormone stimulus;cellular response to peptide hormone stimulus;positive regulation of steroid hormone biosynthetic process;cellular organofluorine metabolic process
- Cellular component
- mitochondrion;endoplasmic reticulum membrane;cytosol;membrane;integral component of membrane;intracellular membrane-bounded organelle
- Molecular function
- NADPH-hemoprotein reductase activity;cytochrome-b5 reductase activity, acting on NAD(P)H;protein binding;nitric oxide dioxygenase activity;electron transfer activity;FMN binding;oxidoreductase activity;hydrolase activity;enzyme binding;iron-cytochrome-c reductase activity;flavin adenine dinucleotide binding;NADP binding